COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,441 Articles (22,835 medRxiv, 8,606 bioRxiv)

Most recent first Previous |  Page 1802: Articles 18011-18020  | Next

What is the extent of COVID-19 vaccine hesitancy in Bangladesh? : A cross-sectional rapid national survey
Ali, M., Hossain, A.
10.1101/2021.02.17.21251917 — Posted: 2021-02-22 Discussion: Onsite
Methodological Approach for Wastewater Based Epidemiological Studies for SARS-CoV-2
Kopperi, H., Tharak, A., Hemalatha, M., Kiran, U., Gokulan, C. G., Mishra, R. K., Venkata Mohan, S.
10.1101/2021.02.17.21251905 — Posted: 2021-02-22 Discussion: Onsite
Targeting the Coronavirus Nucleocapsid Protein through GSK-3 Inhibition
Liu, X., Verma, A., Ramage, H., Garcia, G., Myers, R. L., Lucas, A., Michaelson, J. J., Coryell, W., Kumar, A., Charney, A., Kazanietz, M. G., Rader, D. J., Ritchie, M. D., Berrettini, W. H., Damoiseaux, R., Arumugaswami, V., Schultz, D., Cherry, S., Klein, P. S.
10.1101/2021.02.17.21251933 — Posted: 2021-02-22
Diagnostic accuracy of RT-PCR for detection of SARS-CoV-2 compared to a composite reference standard in hospitalized patients
Stefanovic, A., Reich, N., Lowe, C. F., Puddicombe, D., Matic, N., Greiner, J., Simons, J., Leung, V., Chu, T., Naik, H., Myles, N., Burns, L., Romney, M. G., Ritchie, G., Champagne, S., Dooley, K., Sekirov, I.
10.1101/2021.02.18.21252016 — Posted: 2021-02-22
Demographic benchmarks for equitable coverage of the COVID-19 vaccination program among priority populations
Vashist, K., Akintobi, T., Bednarczyk, R. A., Narayan, K. M. V., Patel, S. A.
10.1101/2021.02.18.21251992 — Posted: 2021-02-22
Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies : Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations
Verkhivker, G., Agajanian, S., Oztas, D. Y., Gupta, G.
10.1101/2021.02.21.432165 — Posted: 2021-02-22
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Starr, T. N., Greaney, A. J., Dingens, A. S., Bloom, J. D.
10.1101/2021.02.17.431683 — Posted: 2021-02-22 Discussion: Onsite
A novel glucocorticoid and androgen receptor modulator reduces viral entry and innate immune inflammatory responses in the Syrian Hamster model of SARS-CoV-2
Rocha, S. M., Fagre, A. C., Latham, A. S., Popichak, K. A., McDermott, C. P., Dawson, C. C., Lewis, J., Reigan, P., Aboellail, T. A., Kading, R. C., Schountz, T., Theise, N. D., Slayden, R. A., Tjalkens, R. B.
10.1101/2021.02.20.432110 — Posted: 2021-02-22
Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., Patel, S., Byram, R., Gomes, D. N., Michael, G., Abdullahi, H., Beydoun, N., Panganiban, B., McNair, N., Hellmeister, K., Pitts, J., Winters, J., Kleinhenz, J., Usher, J., O'Keefe, J. B., Piantadosi, A., Waggoner, J. J., Babiker, A., Stephens, D. S., Anderson, E. J., Edupuganti, S., Rouphael, N., Ahmed, R., Wrammert, J., Suthar, M. S.
10.1101/2021.02.20.432046 — Posted: 2021-02-22
Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies
Cerutti, G., Rapp, M., Guo, Y., Bahna, F., Bimela, J., Reddem, E. R., Yu, J., Wang, P., Liu, L., Huang, Y., Ho, D. D., Kwong, P. D., Sheng, Z., Shapiro, L.
10.1101/2021.02.21.432168 — Posted: 2021-02-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).